ASPIRE IPF Phase 2b trial

The encouraging results from the Phase 2a AIR trial support advancement into the Phase 2b ASPIRE IPF trial to investigate the disease modifying potential of buloxibutid (C21) in IPF.

The ASPIRE IPF trial of buloxibutid is being designed in close collaboration with world leading clinical experts and patient advocacy organizations to create a patient and site friendly experience, while ensuring high quality standards are maintained.

Key features of ASPIRE IPF:

A randomized, double-blind, placebo-controlled, parallel group, multicentre trial of two doses of buloxibutid
52 weeks treatment duration
N=270 participants (90/treatment arm)
People with IPF on stable nintedanib or not on SoC
Primary endpoint – change from baseline in FVC

For more information about the ASPIRE IPF trial and recruiting sites see: aspire-ipf.com and NCT06588686.